MA29846B1 - Lignee cellulaire vero convenant a une croissance en suspension - Google Patents

Lignee cellulaire vero convenant a une croissance en suspension

Info

Publication number
MA29846B1
MA29846B1 MA30809A MA30809A MA29846B1 MA 29846 B1 MA29846 B1 MA 29846B1 MA 30809 A MA30809 A MA 30809A MA 30809 A MA30809 A MA 30809A MA 29846 B1 MA29846 B1 MA 29846B1
Authority
MA
Morocco
Prior art keywords
cell line
relates
vero cell
suspended growth
grow
Prior art date
Application number
MA30809A
Other languages
English (en)
Inventor
Marcelo Gustavo Daelli
Angela Guillermina Forno
Cristian Paillet
Marina Etcheverrigaray
Ricardo Kratje
Original Assignee
Zelltek S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zelltek S A filed Critical Zelltek S A
Publication of MA29846B1 publication Critical patent/MA29846B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C12N2500/95—Protein-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention porte sur une lignée cellulaire Vero qui peut croître dans une culture dépourvue de sérum et de protéines, en suspension, en l'absence de matériaux de support pour son adhérence. Elle porte aussi sur la production de vaccins viraux utilisant la dite lignée cellulaire. Plus spécifiquement, l'invention concerne l'établissement d'une lignée cellulaire pouvant croître dans une culture en suspension, sans qu'il soit nécessaire que lesdites cellules adhèrent à un matériau de support. L'invention comprend également un procédé pour obtenir ladite lignée cellulaire Vero, ainsi qu'un procédé pour l'obtention de vaccins viraux avec ladite lignée cellulaire. L'invention concerne encore les virus obtenus selon ledit procédé et les vaccins formulés avec lesdits virus.
MA30809A 2005-10-04 2008-04-03 Lignee cellulaire vero convenant a une croissance en suspension MA29846B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72337705P 2005-10-04 2005-10-04

Publications (1)

Publication Number Publication Date
MA29846B1 true MA29846B1 (fr) 2008-10-03

Family

ID=37906536

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30809A MA29846B1 (fr) 2005-10-04 2008-04-03 Lignee cellulaire vero convenant a une croissance en suspension

Country Status (13)

Country Link
US (2) US20070111309A1 (fr)
EP (1) EP1942182B1 (fr)
AR (1) AR058810A1 (fr)
AT (1) ATE552335T1 (fr)
AU (1) AU2006298624B8 (fr)
BR (1) BRPI0616675A2 (fr)
CA (1) CA2624544C (fr)
CO (1) CO5910042A1 (fr)
ES (1) ES2385930T3 (fr)
IL (1) IL190578A (fr)
MA (1) MA29846B1 (fr)
WO (1) WO2007039662A2 (fr)
ZA (1) ZA200802936B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982240B2 (en) 2012-08-03 2018-05-29 Sanofi Pasteur Production of infectious influenza viruses
EP3105311A1 (fr) 2014-02-10 2016-12-21 Univercells NV Système, appareil et procédé de production de biomolécules
KR101831284B1 (ko) * 2017-06-26 2018-02-22 에스케이케미칼 주식회사 무혈청 배지에서 부유배양 되는 Vero 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
CN107267443B (zh) * 2017-07-27 2020-06-05 郑州爱科生物科技有限公司 一种适应全悬浮培养的vero E6细胞株及其应用
WO2019090565A1 (fr) * 2017-11-09 2019-05-16 甘肃健顺生物科技有限公司 Procédé d'acclimatation et de mise en suspension de vero et procédé de production de second ordre pour virus
CN107937349B (zh) * 2017-11-27 2021-01-15 中国检验检疫科学研究院 稳定表达非洲猪瘟病毒p54蛋白的细胞系及其制备与应用
CN110904025A (zh) * 2019-10-08 2020-03-24 上海源培生物科技股份有限公司 Vero细胞的无血清悬浮驯化方法
WO2021107612A1 (fr) * 2019-11-27 2021-06-03 에스케이바이오사이언스 주식회사 Nouvelle lignée cellulaire vero pouvant être cultivée en suspension dans un milieu sans sérum, son procédé de préparation et procédé de préparation de virus pour vaccins à l'aide d'une nouvelle lignée cellulaire
CN111849869A (zh) * 2020-08-06 2020-10-30 百奥特生物科技(上海)有限公司 一种用于vero细胞的无血清培养基

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
US4525349A (en) * 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
FR2543158B1 (fr) * 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US4664912A (en) * 1984-10-01 1987-05-12 Wiktor Tadeusz J Process for the large scale production of rabies vaccine
US4783407A (en) * 1985-09-30 1988-11-08 Merck & Co., Inc. Growth of hepatitus A virus in vero cells
US5719051A (en) * 1989-12-22 1998-02-17 Immuno Aktiengesellschaft Perfusion system and a method for the large scale production of virus or virus antigen
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
FR2737730B1 (fr) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US6656719B1 (en) * 1997-10-27 2003-12-02 Merck & Co., Inc. Serum-free, low-protein media for rotavirus vaccine production
US6793926B1 (en) * 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
AU2001236042B9 (en) * 2000-03-03 2006-06-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
DK1358319T3 (da) * 2000-09-25 2009-10-05 Polymun Scient Immunbio Forsch Levende influenzavaccine og fremgangsmåde til fremstilling heraf
JP2007515172A (ja) * 2003-12-23 2007-06-14 シェーリング　コーポレイション 無血清培地懸濁培養において安定なａ５４９細胞株を生成するための方法

Also Published As

Publication number Publication date
AU2006298624B2 (en) 2012-05-31
EP1942182A4 (fr) 2009-11-25
ES2385930T3 (es) 2012-08-03
CO5910042A1 (es) 2008-04-30
ATE552335T1 (de) 2012-04-15
BRPI0616675A2 (pt) 2011-06-28
US20090203112A1 (en) 2009-08-13
IL190578A (en) 2013-10-31
AU2006298624B8 (en) 2012-06-14
AR058810A1 (es) 2008-02-27
WO2007039662B1 (fr) 2007-06-28
WO2007039662A2 (fr) 2007-04-12
WO2007039662A3 (fr) 2007-05-24
ZA200802936B (en) 2009-12-30
CA2624544C (fr) 2012-07-17
US20070111309A1 (en) 2007-05-17
AU2006298624A1 (en) 2007-04-12
EP1942182B1 (fr) 2012-04-04
CA2624544A1 (fr) 2007-04-12
IL190578A0 (en) 2008-11-03
EP1942182A2 (fr) 2008-07-09

Similar Documents

Publication Publication Date Title
MA29846B1 (fr) Lignee cellulaire vero convenant a une croissance en suspension
WO2006071563A3 (fr) Lignee cellulaire mdck non-oncogene destinee a propager des virus
MA27631A1 (fr) Procede de culture cellulaire n'utilisant pas de composants d'origine animale
EP2471903A3 (fr) Populations de cellules souches placentaires
RU2010125605A (ru) Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
MX2007005132A (es) Medios libres de proteina animal para cultivo de celulas.
DE602004014526D1 (de) Immortalisierte vogelzellinien zur virusproduktion
ATE430807T1 (de) Verfahren zur kultivierung von circovirus
EA200501774A1 (ru) Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции
DE60216959D1 (de) Sich in schlagende kardiomyozyten verwandelnde stammzellen
WO2007016366A3 (fr) Conditions definies de culture de cellules souches embryonnaires humaines
NZ591292A (en) Improved cell composition and methods of making the same
EP2444483A3 (fr) Matériaux et procédés liés aux thérapies cellulaires
EP1904624A4 (fr) Procédé pour cultiver et faire proliférer des cellules souches hématopoïétiques et des cellules progénitrices utilisant des cellules endométriales humaines
NO20033396D0 (no) Forbedret in vitro fremgangsmåte for kultivering av mammale celler for autolog celle implantasjon/transplantasjon fremgangsmåter
Cervera et al. Extended gene expression by medium exchange and repeated transient transfection for recombinant protein production enhancement
WO2010020876A3 (fr) Procédé de culture cellulaire
DK1620549T3 (da) Fremgangsmåde til fremstilling af biologiske stoffer ved perfusionsdyrkning af suspenderede dyreceller
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
DK1733024T3 (da) Fremgangsmåde til fremstilling af en cellesammensætning indeholdende epithelceller
WO2003069972A3 (fr) Lignees cellulaires precurseurs d'hepatocytes
EP2377922A3 (fr) Endoderme exprimant PDX1
WO2000059525A3 (fr) UTILISATION DE LIGANDS RECEPTEURS DE ErbB DANS LE TRAITEMENT DU DIABETE
DE602006014534D1 (de) Herstellung und verwendung von basalmembranpartikeln
ATE366803T1 (de) Hohe zytokinproduktion mit verbesserte zelllebensfähigkeit